Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman… - Brain, 2016 - academic.oup.com
A number of studies have been conducted with the onset of secondary progressive multiple
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial
Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …
kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which …
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
T Kalincik, JWL Brown, N Robertson, M Willis… - The Lancet …, 2017 - thelancet.com
Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
D Cadavid, M Mellion, R Hupperts… - The Lancet …, 2019 - thelancet.com
Background Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor of
oligodendrocyte differentiation and axonal regeneration. Previous findings suggested that …
oligodendrocyte differentiation and axonal regeneration. Previous findings suggested that …
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
Background There is an unmet need to develop therapeutic interventions directed at the
neurodegeneration that underlies progression in multiple sclerosis. High-dose …
neurodegeneration that underlies progression in multiple sclerosis. High-dose …
Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years
Objective To test the hypothesis that immunotherapy prevents long-term disability in
relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 …
relapsing-remitting multiple sclerosis (MS), we modeled disability outcomes in 14,717 …
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis;
however, treatment response varies greatly among patients. Comprehensive predictive …
however, treatment response varies greatly among patients. Comprehensive predictive …
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
T Kalincik, EK Havrdova, D Horakova… - Journal of Neurology …, 2019 - jnnp.bmj.com
Objective Oral immunotherapies have become a standard treatment in relapsing-remitting
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
multiple sclerosis. Direct comparison of their effect on relapse and disability is needed …
Risk of secondary progressive multiple sclerosis: a longitudinal study
A Fambiatos, V Jokubaitis, D Horakova… - Multiple Sclerosis …, 2020 - journals.sagepub.com
Background: The risk factors for conversion from relapsing-remitting to secondary
progressive multiple sclerosis remain highly contested. Objective: The aim of this study was …
progressive multiple sclerosis remain highly contested. Objective: The aim of this study was …
Natalizumab, fingolimod, and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis
Objective To investigate pregnancy-related disease activity in a contemporary multiple
sclerosis (MS) cohort. Methods Using data from the MSBase Registry, we included …
sclerosis (MS) cohort. Methods Using data from the MSBase Registry, we included …